Table of Contents Introduction Dyslipidemia - Overview Dyslipidemia - Therapeutics Development Dyslipidemia - Therapeutics Assessment Dyslipidemia - Companies Involved in Therapeutics Development Dyslipidemia - Drug Profiles Dyslipidemia - Dormant Projects Dyslipidemia - Discontinued Products Dyslipidemia - Product Development Milestones Appendix

List of Tables Number of Products under Development for Dyslipidemia, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products under Development by Universities/Institutes, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Universities/Institutes, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Dyslipidemia - Pipeline by AbbVie Inc, H1 2019 Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2019 Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2019 Dyslipidemia - Pipeline by Amarin Corp Plc, H1 2019 Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2019 Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2019 Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2019 Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2019 Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2019 Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H1 2019 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2019 Dyslipidemia - Pipeline by Cardax Inc, H1 2019 Dyslipidemia - Dormant Projects, H1 2019 Dyslipidemia - Discontinued Products, H1 2019List of Figures Number of Products under Development for Dyslipidemia, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products under Development by Universities/Institutes, H1 2019 Number of Products by Top 10 Targets, H1 2019 Number of Products by Stage and Top 10 Targets, H1 2019 Number of Products by Top 10 Mechanism of Actions, H1 2019 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

AbbVie Inc Acasti Pharma Inc Akcea Therapeutics Inc Amarin Corp Plc Arrowhead Pharmaceuticals Inc AstraZeneca Plc BCWorld Pharm Co Ltd BioRestorative Therapies Inc Boryung Pharmaceutical Co Ltd Cadila Healthcare Ltd Cadila Pharmaceuticals Ltd Cardax Inc Celon Pharma SA Cerenis Therapeutics Holding SA Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Corvidia Therapeutics Inc Daewon Pharm Co Ltd Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Co Ltd Eli Lilly and Co Esperion Therapeutics Inc Gemphire Therapeutics Inc Gilead Sciences Inc Golden Biotechnology Corp Handok Inc Hanlim Pharm Co Ltd Ildong Pharmaceutical Co Ltd Inovio Pharmaceuticals Inc InStar Technologies AS Jeil Pharmaceutical Co Ltd Jenrin Discovery Inc Kotobuki Pharmaceutical Co Ltd Kowa Co Ltd Kuhnil Pharmaceutical Co Ltd Kyorin Pharmaceutical Co Ltd LG Chem Ltd LipimetiX Development Inc Matinas BioPharma Holdings Inc Mochida Pharmaceutical Co Ltd Nippon Chemiphar Co Ltd NorthSea Therapeutics BV Novartis AG NuSirt Biopharma Inc Omeros Corp Pharmena SA Regeneron Pharmaceuticals Inc Sancilio & Company Inc Shanghai Junshi Bioscience Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd SJT Molecular Research SL Suzhou Ribo Life Sciences Co Ltd Viking Therapeutics Inc Yuhan Corp